{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:25:10Z","timestamp":1793744710646,"version":"4.6.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03360-y","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T17:12:11Z","timestamp":1754241131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015\u20132024)"],"prefix":"10.1007","volume":"16","author":[{"given":"Moutaz W.","family":"Sweileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"issue":"6","key":"3360_CR1","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 2019;42(6):2183\u201395. Epub 20190924. doi: 10.3892\/or.2019.7335. PubMed PMID: 31578576.","journal-title":"Oncol Rep"},{"issue":"17","key":"3360_CR2","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: cars take the front seat for hematologic malignancies. Blood. 2014;123(17):2625\u201335. https:\/\/doi.org\/10.1182\/blood-2013-11-492231. Epub 20140227.","journal-title":"Blood"},{"issue":"8","key":"3360_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502. Epub 20150711. doi: 10.1016\/j.it.2015.06.004. PubMed PMID: 26169254; PubMed Central PMCID: PMC4746114.","journal-title":"Trends Immunol"},{"issue":"6382","key":"3360_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711. PubMed PMID: 29567707.","journal-title":"Science"},{"issue":"4","key":"3360_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","volume":"18","author":"AM DiNofia","year":"2021","unstructured":"DiNofia AM, Grupp SA. Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells \u2018off the shelf\u2019? Nat Rev Clin Oncol. 2021;18(4):195\u20136. https:\/\/doi.org\/10.1038\/s41571-021-00485-1. PubMed PMID: 33608691.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3360_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2. Epub 20200103.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3360_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z. Epub 20210122.","journal-title":"Nat Rev Cancer"},{"issue":"16\u201317","key":"3360_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/1750743X.2024.2408048","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Gao Y, Zhang Y. Allogeneic CAR-T cells for cancer immunotherapy. Immunotherapy. 2024;16(16\u201317):1079\u201390. Epub 20241008. doi: 10.1080\/1750743x.2024.2408048. PubMed PMID: 39378059; PubMed Central PMCID: PMC11492692.","journal-title":"Immunotherapy"},{"key":"3360_CR9","doi-asserted-by":"publisher","first-page":"1270843","DOI":"10.3389\/fimmu.2023.1270843","volume":"14","author":"C Calvi\u00f1o","year":"2023","unstructured":"Calvi\u00f1o C, Ceballos C, Alfonso A, Jauregui P, Calleja-Cervantes ME, San Martin-Uriz P, et al. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia. Front Immunol. 2023;14:1270843. PubMed PMID: 37795087; PubMed Central PMCID: PMC10546312.","journal-title":"Front Immunol"},{"issue":"4","key":"3360_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.Cir-23-0679","volume":"12","author":"\u00c9 Degagn\u00e9","year":"2024","unstructured":"Degagn\u00e9 \u00c9, Donohoue PD, Roy S, Scherer J, Fowler TW, Davis RT, et al. High-Specificity CRISPR-Mediated genome engineering in Anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. Cancer Immunol Res. 2024;12(4):462\u201377. https:\/\/doi.org\/10.1158\/2326-6066.Cir-23-0679. PubMed PMID: 38345397; PubMed Central PMCID: PMC10985478.","journal-title":"Cancer Immunol Res"},{"key":"3360_CR11","unstructured":"U.S, Food. & Drug Administration. Cellular & gene therapy products. 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products. Accessed 10 Apr 2025."},{"key":"3360_CR12","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153. Epub 20220610.","journal-title":"Front Immunol"},{"issue":"4","key":"3360_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7. Epub 20210406.","journal-title":"Blood Cancer J"},{"issue":"6","key":"3360_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/ejh.13851","volume":"109","author":"DM Pasqui","year":"2022","unstructured":"Pasqui DM, Latorraca C, Pacheco RL, Riera R. CAR-T cell therapy for patients with hematological malignancies. A systematic review. Eur J Haematol. 2022;109(6):601\u201318. https:\/\/doi.org\/10.1111\/ejh.13851. Epub 20220918.","journal-title":"Eur J Haematol"},{"key":"3360_CR15","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049. Epub 20230515.","journal-title":"Front Immunol"},{"issue":"22","key":"3360_CR16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-Cell therapies for cancer: A translational science review. JAMA. 2024;332(22):1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462. PubMed PMID: 39495525; PubMed Central PMCID: PMC11808657.","journal-title":"JAMA"},{"key":"3360_CR17","doi-asserted-by":"publisher","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","volume":"13","author":"LS Boussi","year":"2022","unstructured":"Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022;13:1027385. Epub 20221028. doi: 10.3389\/fimmu.2022.1027385. PubMed PMID: 36389674; PubMed Central PMCID: PMC9649817.","journal-title":"Front Immunol"},{"key":"3360_CR18","doi-asserted-by":"publisher","first-page":"104590","DOI":"10.1016\/j.msard.2023.104590","volume":"70","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA. Are we ready for CD19-targeted CAR T-cell therapies in MS? Mult Scler Relat Disord. 2023;70:104590. https:\/\/doi.org\/10.1016\/j.msard.2023.104590. Epub 20230225.","journal-title":"Mult Scler Relat Disord"},{"key":"3360_CR19","doi-asserted-by":"publisher","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2). https:\/\/doi.org\/10.1084\/jem.20230903.","DOI":"10.1084\/jem.20230903"},{"issue":"5","key":"3360_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.seminhematol.2024.07","volume":"61","author":"D Blud","year":"2024","unstructured":"Blud D, Rubio-Reyes P, Perret R, Weinkove R. Tuning CAR T-cell therapies for efficacy and reduced toxicity. Semin Hematol. 2024;61(5):333\u201344. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.07. Epub 20240706.","journal-title":"Semin Hematol"},{"key":"3360_CR21","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266. Epub 20240801.","journal-title":"EBioMedicine"},{"issue":"4","key":"3360_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell M, Lange S, Sejdiu BI, Ibanez J, Shi H, Sun X, et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat Biomed Eng. 2024;8(4):380\u201396. https:\/\/doi.org\/10.1038\/s41551-023-01143-w. Epub 20231130.","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"3360_CR23","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1002\/acg2.84","volume":"3","author":"M Chmielewski","year":"2020","unstructured":"Chmielewski M, Abken H. TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation. Adv Cell Gene Therapy. 2020;3(3):e84. https:\/\/doi.org\/10.1002\/acg2.84.","journal-title":"Adv CELL GENE THERAPY"},{"key":"3360_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res. 2021;133:285\u201396. https:\/\/doi.org\/10.1016\/j.jbusres.2021.04.070.","journal-title":"J Bus Res"},{"issue":"4","key":"3360_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.joi.2014.07.006","volume":"8","author":"NJ van Eck","year":"2014","unstructured":"van Eck NJ, Waltman L, CitNetExplorer:. A new software tool for analyzing and visualizing citation networks. J Informetrics. 2014;8(4):802\u201323. https:\/\/doi.org\/10.1016\/j.joi.2014.07.006.","journal-title":"J Informetrics"},{"key":"3360_CR26","doi-asserted-by":"publisher","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523\u2013\u200938. https:\/\/doi.org\/10.1007\/s11192-009-0146-3.","DOI":"10.1007\/s11192-009-0146-3"},{"issue":"12","key":"3360_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15252\/embr.201439608","volume":"15","author":"L Bornmann","year":"2014","unstructured":"Bornmann L, Leydesdorff L. Scientometrics in a changing research landscape. EMBO Rep. 2014;15(12):1228\u201332. https:\/\/doi.org\/10.15252\/embr.201439608.","journal-title":"EMBO Rep"},{"issue":"1","key":"3360_CR28","doi-asserted-by":"publisher","first-page":"2371664","DOI":"10.1080\/21645515.2024.2371664","volume":"20","author":"Q Huang","year":"2024","unstructured":"Huang Q, Li H, Zhang Y. A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023. Hum Vaccin Immunother. 2024;20(1):2371664. PubMed PMID: 38961667; PubMed Central PMCID: PMC11225924.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"3360_CR29","doi-asserted-by":"publisher","first-page":"2291900","DOI":"10.1080\/21645515.2023.2291900","volume":"19","author":"H Li","year":"2023","unstructured":"Li H, Huang Q, Zhang Y. A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023. Hum Vaccin Immunother. 2023;19(3):2291900. PubMed PMID: 38112002; PubMed Central PMCID: PMC10732679.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3360_CR30","doi-asserted-by":"publisher","first-page":"2415187","DOI":"10.1080\/21645515.2024.2415187","volume":"20","author":"W Li","year":"2024","unstructured":"Li W, Feng J, Peng J, Zhang X, Aziz AUR, Wang D. Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023. Hum Vaccin Immunother. 2024;20(1):2415187. PubMed PMID: 39414236; PubMed Central PMCID: PMC11486046.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3360_CR31","doi-asserted-by":"publisher","first-page":"2338984","DOI":"10.1080\/21645515.2024.2338984","volume":"20","author":"L Miao","year":"2024","unstructured":"Miao L, Zhang J, Xu W, Qian Q, Zhang G, Yuan Q, et al. Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012\u20132023). Hum Vaccin Immunother. 2024;20(1):2338984. PubMed PMID: 38698555; PubMed Central PMCID: PMC11073418.","journal-title":"Hum Vaccin Immunother"},{"key":"3360_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840956","author":"L Miao","year":"2022","unstructured":"Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, et al. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. Front Immunol. 2022;13:840956. https:\/\/doi.org\/10.3389\/fimmu.2022.840956. Epub 20220318."},{"issue":"3","key":"3360_CR33","doi-asserted-by":"publisher","first-page":"2267865","DOI":"10.1080\/21645515.2023.2267865","volume":"19","author":"L Ou","year":"2023","unstructured":"Ou L, Su C, Liang L, Duan Q, Li Y, Zang H, et al. Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis. Hum Vaccin Immunother. 2023;19(3):2267865. PubMed PMID: 37846106; PubMed Central PMCID: PMC10583622.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"3360_CR34","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1080\/21645515.2021.1947100","volume":"17","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Fu Q, Zhang Y, Xu D, Wu Y, Qiu Q, et al. CAR-based cell therapy: evaluation with bibliometrics and patent analysis. Hum Vaccin Immunother. 2021;17(11):4374\u201382. PubMed PMID: 34184975; PubMed Central PMCID: PMC8827635.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3360_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13643-023-02410-2","volume":"12","author":"A Montazeri","year":"2023","unstructured":"Montazeri A, Mohammadi S, P MH, Ghaemi M, Riazi H, Sheikhi-Mobarakeh Z. Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements. Syst Rev. 2023;12(1):239. https:\/\/doi.org\/10.1186\/s13643-023-02410-2. Epub 20231215.","journal-title":"Syst Rev"},{"issue":"6","key":"3360_CR36","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/ehf2.12583","volume":"6","author":"MS Anker","year":"2019","unstructured":"Anker MS, Hadzibegovic S, Lena A, Haverkamp W. The difference in referencing in web of science, scopus, and Google scholar. ESC Heart Fail. 2019;6(6):1291\u2013312. https:\/\/doi.org\/10.1002\/ehf2.12583. Epub 20191230.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3360_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.outlook.2012.04.007","volume":"60","author":"SL De Groote","year":"2012","unstructured":"De Groote SL, Raszewski R. Coverage of Google scholar, scopus, and web of science: a case study of the h-index in nursing. Nurs Outlook. 2012;60(6):391\u2013400. https:\/\/doi.org\/10.1016\/j.outlook.2012.04.007. Epub 20120630.","journal-title":"Nurs Outlook"},{"key":"3360_CR38","doi-asserted-by":"publisher","unstructured":"Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. Faseb J. 2008;22(2):338\u201342. https:\/\/doi.org\/10.1096\/fj.07-9492LSF.","DOI":"10.1096\/fj.07-9492LSF"},{"issue":"1","key":"3360_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12889-018-5689-x","volume":"18","author":"WM Sweileh","year":"2018","unstructured":"Sweileh WM, Wickramage K, Pottie K, Hui C, Roberts B, Sawalha AF, et al. Bibliometric analysis of global migration health research in peer-reviewed literature (2000\u20132016). BMC Public Health. 2018;18(1):777. https:\/\/doi.org\/10.1186\/s12889-018-5689-x. Epub 20180620.","journal-title":"BMC Public Health"},{"key":"3360_CR40","volume-title":"Introduction to informetrics. Quantitative methods in library","author":"L Egghe","year":"1990","unstructured":"Egghe L, Rousseau R. Introduction to informetrics. Quantitative methods in library. documentation and information science: Elsevier Science; 1990."},{"issue":"3","key":"3360_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","volume":"110","author":"H Arruda","year":"2022","unstructured":"Arruda H, Silva ER, Lessa M, Proen\u00e7a D Jr., Bartholo R. VOSviewer and bibliometrix. J Med Libr Assoc. 2022;110(3):392\u20135. https:\/\/doi.org\/10.5195\/jmla.2022.1434. PubMed PMID: 36589296; PubMed Central PMCID: PMC9782747.","journal-title":"J Med Libr Assoc"},{"issue":"46","key":"3360_CR42","doi-asserted-by":"publisher","first-page":"16569","DOI":"10.1073\/pnas.0507655102","volume":"102","author":"JE Hirsch","year":"2005","unstructured":"Hirsch JE. An index to quantify an individual\u2019s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46):16569\u201372. Epub 20051107. doi: 10.1073\/pnas.0507655102. PubMed PMID: 16275915; PubMed Central PMCID: PMC1283832.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3360_CR43","doi-asserted-by":"publisher","first-page":"102339","DOI":"10.1016\/j.mex.2023.102339","volume":"11","author":"UA Bukar","year":"2023","unstructured":"Bukar UA, Sayeed MS, Razak SFA, Yogarayan S, Amodu OA, Mahmood RAR. A method for analyzing text using VOSviewer. MethodsX. 2023;11:102339. https:\/\/doi.org\/10.1016\/j.mex.2023.102339.","journal-title":"MethodsX"},{"issue":"1","key":"3360_CR44","first-page":"1","volume":"1","author":"NJ Van Eck","year":"2013","unstructured":"Van Eck NJ, Waltman L. VOSviewer manual. Leiden: Univeristeit Leiden. 2013;1(1):1\u201353.","journal-title":"Leiden: Univeristeit Leiden"},{"issue":"3","key":"3360_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/0194262X.2021.1991547","volume":"41","author":"JT McAllister","year":"2022","unstructured":"McAllister JT, Lora L, Atencio Mojica Z, Mapping A, Discipline. A guide to using VOSviewer for bibliometric and visual analysis. Sci Technol Libr. 2022;41(3):319\u201348. https:\/\/doi.org\/10.1080\/0194262X.2021.1991547.","journal-title":"Sci Technol Libr"},{"issue":"26","key":"3360_CR46","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. Epub 20171210. doi: 10.1056\/NEJMoa1707447. PubMed PMID: 29226797; PubMed Central PMCID: PMC5882485.","journal-title":"N Engl J Med"},{"issue":"5","key":"3360_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866. PubMed PMID: 29385370; PubMed Central PMCID: PMC5996391.","journal-title":"N Engl J Med"},{"issue":"1","key":"3360_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. Epub 20181201. doi: 10.1056\/NEJMoa1804980. PubMed PMID: 30501490.","journal-title":"N Engl J Med"},{"issue":"1","key":"3360_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342. PubMed PMID: 30518502; PubMed Central PMCID: PMC6733402.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3360_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640\u201354. Epub 20211211. doi: 10.1056\/NEJMoa2116133. PubMed PMID: 34891224.","journal-title":"N Engl J Med"},{"issue":"8","key":"3360_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. doi: 10.1056\/NEJMoa2024850. PubMed PMID: 33626253.","journal-title":"N Engl J Med"},{"issue":"10297","key":"3360_CR52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/s0140-6736. Epub 20210624.","journal-title":"Lancet"},{"issue":"27","key":"3360_CR53","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/jco.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-Care Axicabtagene Ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119\u201328. https:\/\/doi.org\/10.1200\/jco.19.02104. Epub 20200513.","journal-title":"J Clin Oncol"},{"key":"3360_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355. Epub 20181114. doi: 10.1016\/j.blre.2018.11.002. PubMed PMID: 30528964; PubMed Central PMCID: PMC6628697.","journal-title":"Blood Rev"},{"issue":"7","key":"3360_CR55","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-Line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J Med. 2022;386(7):629\u201339. Epub 20211214. doi: 10.1056\/NEJMoa2116596. PubMed PMID: 34904798.","journal-title":"N Engl J Med"},{"issue":"2","key":"3360_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0. Epub 20211217.","journal-title":"Nat Med"},{"issue":"10","key":"3360_CR57","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315. Epub 20210910. doi: 10.1016\/s1470-2045(21)00375-2. PubMed PMID: 34516954.","journal-title":"Lancet Oncol"},{"issue":"21","key":"3360_CR58","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood.2022017564","volume":"140","author":"N Ghosh","year":"2022","unstructured":"Ghosh N. Axi-cel in LBCL: fulfill two needs with one deed. Blood. 2022;140(21):2183\u20135. https:\/\/doi.org\/10.1182\/blood.2022017564. PubMed PMID: 36422859.","journal-title":"Blood"},{"issue":"9","key":"3360_CR59","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848\u201359. https:\/\/doi.org\/10.1038\/s41591-022-01959-0. Epub 20220912.","journal-title":"Nat Med"},{"issue":"6","key":"3360_CR60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of Axicabtagene Ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496\u2013506. PubMed PMID: 37879047; PubMed Central PMCID: PMC10934297.","journal-title":"Blood"},{"issue":"9","key":"3360_CR61","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41571-023-00793-8","volume":"20","author":"D Romero","year":"2023","unstructured":"Romero D. Second-line axi-cel improves overall survival. Nat Rev Clin Oncol. 2023;20(9):579. https:\/\/doi.org\/10.1038\/s41571-023-00793-8. PubMed PMID: 37311903.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3360_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with Axicabtagene Ciloleucel in large B-Cell lymphoma. N Engl J Med. 2023;389(2):148\u201357. Epub 20230605. doi: 10.1056\/NEJMoa2301665. PubMed PMID: 37272527.","journal-title":"N Engl J Med"},{"issue":"10","key":"3360_CR63","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and Axicabtagene Ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354. https:\/\/doi.org\/10.1038\/s41591-022-01969-y. Epub 20220922.","journal-title":"Nat Med"},{"key":"3360_CR64","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A et al. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30(6):584.e1-.e13. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.074","DOI":"10.1016\/j.jtct.2024.01.074"},{"issue":"14","key":"3360_CR65","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene Maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384. https:\/\/doi.org\/10.1182\/blood.2022018730. PubMed PMID: 36542826; PubMed Central PMCID: PMC10646768.","journal-title":"Blood"},{"issue":"9","key":"3360_CR66","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14712598.2021.1933939","volume":"21","author":"C Iragavarapu","year":"2021","unstructured":"Iragavarapu C, Hildebrandt G. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. Expert Opin Biol Ther. 2021;21(9):1151\u20136. 1933939. PubMed PMID: 34030548.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"3360_CR67","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/s1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene Maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for Haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066\u201377. https:\/\/doi.org\/10.1016\/s1470-2045(22)00339-4. Epub 20220712.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3360_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fon-2022-0774","volume":"19","author":"F St-Pierre","year":"2023","unstructured":"St-Pierre F, Gordon LI. Lisocabtagene Maraleucel in the treatment of relapsed\/refractory large B-cell lymphoma. Future Oncol. 2023;19(1):19\u201328. Epub 20230118. doi: 10.2217\/fon-2022-0774. PubMed PMID: 36651471.","journal-title":"Future Oncol"},{"issue":"4","key":"3360_CR69","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.hemonc.2021.09.004","volume":"15","author":"MA Kharfan-Dabaja","year":"2022","unstructured":"Kharfan-Dabaja MA, Yassine F, Moustafa MA, Iqbal M, Murthy H. Lisocabtagene Maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence?? Hematol Oncol Stem Cell Ther. 2022;15(4):168\u201375. https:\/\/doi.org\/10.1016\/j.hemonc.2021.09.004. Epub 20221223.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"3360_CR70","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","volume":"61","author":"GR Nahas","year":"2020","unstructured":"Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4):940\u20133. PubMed PMID: 31793821.","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"3360_CR71","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","volume":"6","author":"JM Logue","year":"2022","unstructured":"Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care Idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6(24):6109\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2022008320. PubMed PMID: 35939783; PubMed Central PMCID: PMC9768247.","journal-title":"Blood Adv"},{"issue":"4","key":"3360_CR72","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl. 2019;25(4):e123\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12. Epub 20181223.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"3360_CR73","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07","volume":"146","author":"CW Freyer","year":"2020","unstructured":"Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2020.07. Epub 20200806.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3360_CR74","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758. Epub 20181225.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"3360_CR75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7. Epub 20230210.","journal-title":"Curr Hematol Malig Rep"},{"issue":"20","key":"3360_CR76","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342. 10.1182\/blood.2022017414. PubMed PMID: 36989488; PubMed Central PMCID: PMC10329191.","journal-title":"Blood"},{"key":"3360_CR77","doi-asserted-by":"crossref","unstructured":"Rees JH. Management of immune effector cell-associated neurotoxicity syndrome (ICANS). In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT\/EHA CAR-T Cell Handbook. Cham (CH): Springer. 2022. pp. 141\u20135.","DOI":"10.1007\/978-3-030-94353-0_27"},{"key":"3360_CR78","doi-asserted-by":"publisher","unstructured":"Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, et al. Single-center experience using Anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022;10(1). https:\/\/doi.org\/10.1136\/jitc-2021-003847.","DOI":"10.1136\/jitc-2021-003847"},{"issue":"7","key":"3360_CR79","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current Understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321. https:\/\/doi.org\/10.1038\/s41571-024-00903-0. Epub 20240520.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3360_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32\u20139. PubMed PMID: 36260735; PubMed Central PMCID: PMC9813524.","journal-title":"Blood Adv"},{"key":"3360_CR81","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490. Epub 20240521. doi: 10.3389\/fonc.2024.1396490. PubMed PMID: 38835382; PubMed Central PMCID: PMC11148294.","journal-title":"Front Oncol"},{"issue":"3","key":"3360_CR82","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transpl. 2021;56(3):552\u201366. https:\/\/doi.org\/10.1038\/s41409-020-01134-4. Epub 20201124.","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"3360_CR83","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-Cell therapy in multiply relapsed or refractory adult large B-Cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319. https:\/\/doi.org\/10.1200\/jco.18.02079. Epub 20190603.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3360_CR84","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"JA Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, et al. Cost-effectiveness of Axicabtagene Ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the united States. J Med Econ. 2018;21(12):1238\u201345. https:\/\/doi.org\/10.1080\/13696998.2018.1529674. Epub 20181016.","journal-title":"J Med Econ"},{"issue":"1","key":"3360_CR85","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/13696998.2023.2260689","volume":"26","author":"ASL Loftager","year":"2023","unstructured":"Loftager ASL, Dan\u00f8 A, Eklund O, Vadgama S, Hedlof Kanje V, Munk E. Axicabtagene Ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial. J Med Econ. 2023;26(1):1303\u201317. 2260689. PubMed PMID: 37725082.","journal-title":"J Med Econ"},{"issue":"6","key":"3360_CR86","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737167.2023.2214731","volume":"23","author":"P Petrou","year":"2023","unstructured":"Petrou P. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):625\u201350. PubMed PMID: 37288738.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"3360_CR87","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","volume":"6","author":"J Furzer","year":"2020","unstructured":"Furzer J, Gupta S, Nathan PC, Schechter T, Pole JD, Krueger J, et al. Cost-effectiveness of tisagenlecleucel vs standard care in High-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol. 2020;6(3):393\u2013401. PubMed PMID: 31971547; PubMed Central PMCID: PMC6990832.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3360_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ejh.13427","volume":"105","author":"FW Thielen","year":"2020","unstructured":"Thielen FW, van Dongen-Leunis A, Arons AMM, Ladestein JR, Hoogerbrugge PM, Uyl-de Groot CA. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. A societal view. Eur J Haematol. 2020;105(2):203\u201315. https:\/\/doi.org\/10.1111\/ejh.13427. Epub 20200504.","journal-title":"Eur J Haematol"},{"issue":"12","key":"3360_CR89","doi-asserted-by":"publisher","first-page":"e2245956","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M. Cost-effectiveness of Axicabtagene Ciloleucel and tisagenlecleucel as Second-line or later therapy in relapsed or refractory diffuse large B-Cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45956. Epub 20221201.","journal-title":"JAMA Netw Open"},{"key":"3360_CR90","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.HS9.0000846712.74284.0f","volume":"6","author":"Y Lin","year":"2022","unstructured":"Lin Y, Martin T, Berdeja JG, Jakubowiak A, Agha M, Cohen AD, et al. P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B\/2 CARTITUDE-1 STUDY. HemaSphere. 2022;6:851\u20132. https:\/\/doi.org\/10.1097\/01.HS9.0000846712.74284.0f. PubMed PMID: 02014419-202206003-00851.","journal-title":"HemaSphere"},{"key":"3360_CR91","doi-asserted-by":"publisher","unstructured":"Yamamoto C, Minakata D, Yokoyama D, Furuki S, Noguchi A, Koyama S et al. Cost-effectiveness of anti-BCMA chimeric antigen receptor T cell therapy in relapsed\/refractory multiple myeloma. Transplant Cell Ther. 2024;30(1):118.e1-.e15. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.001.","DOI":"10.1016\/j.jtct.2023.10.001"},{"issue":"2","key":"3360_CR92","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","volume":"8","author":"JH Choe","year":"2024","unstructured":"Choe JH, Yu T, Abramson JS, Abou-El-Enein M. Cost-effectiveness of second-line lisocabtagene Maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024;8(2):484\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2023011793. PubMed PMID: 38153350; PubMed Central PMCID: PMC10837180.","journal-title":"Blood Adv"},{"issue":"12","key":"3360_CR93","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360. https:\/\/doi.org\/10.7150\/ijbs.34213. Epub 20190907.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3360_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z. Epub 20230130.","journal-title":"Mol Cancer"},{"key":"3360_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139\u201352. https:\/\/doi.org\/10.1146\/annurev-med-062315-120245. Epub 20161117.","journal-title":"Annu Rev Med"},{"issue":"29","key":"3360_CR96","doi-asserted-by":"publisher","first-page":"e34375","DOI":"10.1097\/MD.0000000000034375","volume":"102","author":"S Yilmaz Hanci","year":"2023","unstructured":"Yilmaz Hanci S. Evaluation of the 101 most cited immunology articles: A bibliometric analysis. Med (Baltim). 2023;102(29):e34375.: 10.1097\/md.0000000000034375. PubMed PMID: 37478253; PubMed Central PMCID: PMC10662843.","journal-title":"Med (Baltim)"},{"issue":"3","key":"3360_CR97","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1097\/js9.0000000000001022","volume":"110","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zheng H, Jiang ST, Liu YG, Zhang T, Zhang JW, et al. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis. Int J Surg. 2024;110(3):1699\u2013710. https:\/\/doi.org\/10.1097\/js9.0000000000001022. Epub 20240301.","journal-title":"Int J Surg"},{"issue":"1","key":"3360_CR98","doi-asserted-by":"publisher","first-page":"2440203","DOI":"10.1080\/21645515.2024.2440203","volume":"21","author":"S Zhang","year":"2025","unstructured":"Zhang S, Miao L, Tian X, Yang B, Luo B. Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023. Hum Vaccin Immunother. 2025;21(1):2440203. https:\/\/doi.org\/10.1080\/21645515.2024.2440203. Epub 20250130.","journal-title":"Hum Vaccin Immunother"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03360-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:07:33Z","timestamp":1757336853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03360-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":98,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3360"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03360-y","relation":{"references":[{"id-type":"doi","id":"10.3389\/fimmu.2022.840956","asserted-by":"subject"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,3]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No IRB was required for the current study since all data were obtained from Scopus database and no patients or human subjects were involved directly in the study. No humans or animals or any biological samples were involved in the current study and therefore no consent to participate were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study did not involve any individual person\u2019s data in any form (including individual\u2019s details, Figures, Diagrams, Videos, Images) and therefor consent to publish was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1461"}}